Advertisement Poniard doses first patient in phase I trial - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Poniard doses first patient in phase I trial

Poniard Pharmaceuticals has reported the treatment of the first patient in a phase I clinical trial of the investigational cancer therapy oral picoplatin.

The company previously announced that it had filed an investigational new drug application with the FDA for an oral formulation of picoplatin in February 2007.

The phase I trial is comparing the bioavailability, pharmacokinetics, pharmacodynamics and safety of picoplatin administered orally with picoplatin administered intravenously in approximately 18 patients with advanced solid tumor malignancies. The trial is being conducted at clinical sites in the US and is expected to take six months to complete.